GLP1R and obesity due to melanocortin 4 receptor deficiency: Pharmacological treatments approved for obesity, including orlistat, bupropion–naltrexone, and GLP-1 receptor agonists such as semaglutide, have also shown limited efficacy in modifying lipedema depots [19].